2025 Milestones at the Colorado Center for Personalized Medicine Biobank…
Our team (CCPM in partnership with UCHealth) has reached new heights.
- Over 100,000 biobank participants now have PGx results
- More than 1 million PGx results are available in Epic
These results are not just sitting in charts, they are fueling clinical decision support across the system, helping providers make safer, more appropriate prescribing decisions at the point of care.
And the impact?
- >34,000 drug-gene interaction alerts delivered directly to clinicians
- Coverage across 12 genes and 55 medications
Key high-impact drug–gene pairs supported by clinical decision support span a broad range of medications across multiple areas of medicine, including DPYD–fluoropyrimidines (5-FU, capecitabine); CYP2C19–clopidogrel/SSRIs/PPIs; CYP2D6–opioids (codeine, tramadol), antipsychotics, antidepressants (e.g., venlafaxine, vortioxetine), metoprolol, and ondansetron; TPMT/NUDT15–thiopurines; and SLCO1B1–statins.
Meanwhile, in Clinical Oncology…
The Clinical Oncology PGx program has rapidly scaled from pilot to systemwide implementation, reaching > 1,000 patients who had PGx results returned to Epic.
In just 5 weeks during the summer of 2025, PGx testing in GI Oncology expanded from 5 clinics to 11 clinics across UCHealth.
New clinics onboarded included:
- North: GRMC, MCR, HRMNY
- South: MHC, MHN
- Yampa: YVMC
This marked a major milestone, the first clinical PGx initiative originating on the CU side to be successfully implemented systemwide at UCHealth.
Alerts tied to this initiative are actively informing care by delivering patient-specific chemotherapy and supportive care dosing recommendations, reducing toxicity risk, and optimizing treatment in real time.
And There’s More…
Building on this success, our teams have taken on their next challenge:
- Expansion of clinical-first PGx testing into breast oncology went live February 2, 2026
- Next Expansion: inclusion of all other solid cancer types; go-live date is to be determined
Using the same infrastructure, workflows, and CDS tools developed in GI Oncology, this expansion represents a major step toward scaling precision oncology across disease groups.
Join us next time…
As PGx continues to evolve from innovation to standard of care:
- More patients will receive pre-treatment, actionable genomic insights
- More clinicians will rely on real-time clinical decision support powered by discrete genetic data
- And more lives will be impacted through safer, more precise medication use
CCPM and UCHealth are no longer just piloting pharmacogenomics; we are operationalizing it at scale.
Thank you for joining us for the next phase of our adventure.
[Blog Editor’s note: We can’t wait! I love having smart, effective colleagues]
James Martin, PharmD, MPH
Clinical Pharmacist, Pharmacogenomics Instructor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Colorado Center for Personalized Medicine
Nicole McDaniel, PharmD, MPH
Clinical Pharmacist, Pharmacogenomics Instructor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Colorado Center for Personalized Medicine
